RemeGen Co., Ltd. Completes Successful Placement of H Shares

RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an announcement.

RemeGen Co., Ltd. has successfully completed the placement of 19,000,000 new H Shares, which represents approximately 9.11% of the total issued H Shares and 3.37% of the total issued Shares. This completion, which took place on May 29, 2025, resulted in an increase of the total issued Shares from 544,608,243 to 563,608,243, and the total issued H Shares from 189,581,239 to 208,581,239. The placement was conducted at a price of HK$42.44 per share to at least six independent placees, marking a significant step in the company’s capital expansion efforts.

The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.

More about RemeGen Co. Ltd. Class H

RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biopharmaceutical industry. The company focuses on the development and commercialization of innovative therapies, particularly in the field of oncology and autoimmune diseases.

Average Trading Volume: 9,582,107

Technical Sentiment Signal: Buy

Current Market Cap: HK$31.3B

Find detailed analytics on 9995 stock on TipRanks’ Stock Analysis page.